Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Editorial
Human Papillomavirus (HPV) Vaccine: Is it worthwhile?
Marlene F Shehata* and Alan PaterDepartment of Cellular and Molecular Medicine, University of Ottawa, Ottawa ON, Canada
- Corresponding Author:
- Marlene Shehata R.Ph., BSc. Pharm., MSc. Med., PC., PhD
Clinical Pharmacist Consultant/Cardiovascular Geneticist
Ottawa ON, Canada
Tel: 519-702-5476
Fax: 347-710-5334
E-mail: marlenefouad@yahoo.com
Received date: June 22, 2011; Accepted date: June 22, 2011; Published date: July 22, 2011
Citation: Shehata MF, Pater A (2011) Human Papillomavirus (HPV) Vaccine: Is it worthwhile?. J Biotechnol Biomaterial 1:103e. doi:10.4172/2155-952X.1000103e
Copyright: © 2011 Shehata MF, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Cervical cancer is one of the most common cancers in women. Human Papillomavirus (HPV) is the primary cause of cervical, anal, vulvar, vaginal and penile cancers as well as genital warts. Over 120 types of HPV have been isolated with more than 40 of these types infecting the epithelial lining of the anal and genital tracts [6]. HPV infections can be currently screened using the Pap cytology and the HPV DNA testing [7]. False positive Pap tests can greatly impact the patient’s psychological status and is currently costing over $ 244 M/year [10]. Given the huge economic burden associated with Pap cytology and DNA testing, the purpose of this editorial is to discuss the value of HPV vaccines in preventing HPV infections and hence reducing the economic burden of HPV diagnostic testing.
